Obicetrapib exhibits favorable physiochemical and pharmacokinetic properties compared to previous cholesteryl ester transfer protein inhibitors: An integrated summary of results from non‐human primate studies and clinical trials
Pharmacology Research & Perspectives · 2024-12 · 12 (6)
DOI: 10.1002/prp2.70010 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmacology Research & Perspectives, online erschienen am 18.10.2024. Verfasst von Stephen J Nicholls und 9 weiteren Autor:innen. Beteiligte Einrichtung: Victorian Heart Institute, Monash University, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Cholesterol Ester Transfer Proteins, Oxazolidinones, Macaca fascicularis, Anticholesteremic Agents. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NewAmsterdam Pharma, Naarden, the Netherlands.
Abstract (Originalsprache)
Anacetrapib, a cholesteryl ester transfer protein (CETP) inhibitor previously under development, exhibited an usually extended terminal half‐life and large food effect and accumulated in adipose tissue. Other CETP inhibitors have not shown such effects. Obicetrapib, a potent selective CETP inhibitor, is undergoing Phase III clinical development. Dedicated assessments were conducted in pre‐clinical and Phase I and II clinical studies of obicetrapib to examine the pharmacokinetic issues observed with anacetrapib. After 9 months of dosing up to 50 mg/kg/day in cynomolgus monkeys, obicetrapib was completely eliminated from systemic circulation and not detected in adipose tissue after a 13‐week recovery period. In healthy humans receiving 1–25 mg of obicetrapib, the mean terminal half‐life of obicetrapib was 148, 131, and 121 h at 5, 10, and 25 mg, respectively, and food increased plasma levels by ~1.6‐fold with a 10 mg dose. At the end of treatment in Phase II trials, mean plasma levels of obicetrapib ranged from 194.5 ng/mL with 2.5 mg to 506.3 ng/mL with 10 mg. Plasma levels of obicetrapib decreased by 92.2% and 98.5% at four and 15 weeks post‐treatment, respectively. Obicetrapib shows no clinically relevant accumulation, is minimally affected by food, and has a mean terminal half‐life of 131 h for the 10 mg dose. These data support once daily, chronic dosing of obicetrapib in Phase III trials for dyslipidemia management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Victorian Heart Institute, Monash University, Melbourne, Victoria, Australia.
- NewAmsterdam Pharma B.V, Naarden, The Netherlands.
- Midwest Biomedical Research, Addison, Illinois, USA.
ORCID-Profile: Marc Ditmarsch
Förderung
- NewAmsterdam Pharma, Naarden, the Netherlands
Zitieren
APA
Nicholls, S. J., Nelson, A. J., Kastelein, J. J. P., Ditmarsch, M., Hsieh, A., Johnson, J., Curcio, D., Kling, D., Kirkpatrick, C. F., & Davidson, M. H. (2024). Obicetrapib exhibits favorable physiochemical and pharmacokinetic properties compared to previous cholesteryl ester transfer protein inhibitors: An integrated summary of results from non‐human primate studies and clinical trials. Pharmacology Research & Perspectives, 12(6). https://doi.org/10.1002/prp2.70010
Vancouver
Nicholls SJ, Nelson AJ, Kastelein JJP, Ditmarsch M, Hsieh A, Johnson J, et al. Obicetrapib exhibits favorable physiochemical and pharmacokinetic properties compared to previous cholesteryl ester transfer protein inhibitors: An integrated summary of results from non‐human primate studies and clinical trials. Pharmacology Research & Perspectives. 2024;12(6). doi:10.1002/prp2.70010
BibTeX
@article{Nicholls2024,
author = {Nicholls, Stephen J and Nelson, Adam J and Kastelein, John J P and Ditmarsch, Marc and Hsieh, Andrew and Johnson, Judith and Curcio, Danielle and Kling, Douglas and Kirkpatrick, Carol F and Davidson, Michael H},
title = {Obicetrapib exhibits favorable physiochemical and pharmacokinetic properties compared to previous cholesteryl ester transfer protein inhibitors: An integrated summary of results from non‐human primate studies and clinical trials},
journal = {Pharmacology Research & Perspectives},
year = {2024},
volume = {12},
number = {6},
doi = {10.1002/prp2.70010}
}
EUVIMED